Akirov A, et al. - Given that hyperprolactinemia was common in acromegaly and in these patients, insulin-like growth factor (IGF)-1 level may decrease with dopamine agonist. Researchers presented a series of patients with prolactinoma and a paradoxical increase of IGF-1 levels during cabergoline treatment. The mean adenoma size in the patients involved was 23.8 ± 16.2 mm. An increase of IGF-1 levels to clinically significant levels during cabergoline treatment for PRL-adenoma was seen. In all patients treated with dopamine agonists, IGF-1 monitoring was suggested and not only in those presenting symptoms of acromegaly.